Healthpeak Lifts FY26 FFO Guidance After In-Line Q3, Adds $500M Term Loan
DOC sits 24% above its 52-week low of $15.7.
Summary
Healthpeak posted Q3 2026 net income of $0.02 per share and FFO as Adjusted of $0.44 per share, down from $0.46 a year ago, on revenue of $820.9 million, and raised full-year FFO as Adjusted guidance to $1.76-$1.78 from $1.73-$1.77. Same-store cash NOI guidance moved up to 0.5%-2.0% from 0%-1.5%, helped by senior housing same-store NOI growth of 25.9% at Janus Living (JAN), the majority-owned REIT where revenue rose 78% to $268 million and Adjusted EBITDAre rose 101% to $105 million. GAAP EPS guidance was cut to $0.39-$0.41 from $0.48-$0.52, but the company attributes the drop to depreciation from Janus Living's senior housing acquisitions, which is excluded from FFO. Lab remains the soft spot: same-store NOI fell 0.7%, though occupancy rose 130 bps sequentially and 270 bps since year-end 2025. Healthpeak also lined up a new $500 million undrawn unsecured delayed-draw term loan maturing 2030 and disclosed roughly $233 million of life science acquisitions plus a $38 million Houston medical building leased to HCA. Net debt to Adjusted EBITDAre was 4.7x with $3.8 billion of liquidity as of October 30. The Q3 call is November 3 at 10:00 a.m. ET.
At the time of this announcement, DOC was trading at $19.48 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $13.8B. The 52-week trading range was $15.70 to $22.95. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.